2018
Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice
Maldonado FJ, Al Bawardy BF, Nehra AK, Lee YS, Bruining DH, Adkins MC, Keaveny TM, Johnson MP, Fidler JL, McCollough CH, Fletcher JG. Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice. Inflammatory Bowel Diseases 2018, 25: 1072-1079. PMID: 30476314, DOI: 10.1093/ibd/izy341.Peer-Reviewed Original ResearchConceptsBiomechanical CT analysisBone mineral densityHigh fracture riskHigh-risk groupFracture riskCT enterographyIBD patientsFemoral neck bone mineral densityInflammatory bowel disease patientsNeck bone mineral densityWorld Health Organization classificationConsecutive IBD patientsFracture risk classificationBowel disease patientsFindings of CTMetabolic bone diseaseRetrospective reviewClinical featuresExact prevalenceDisease patientsOrganization classificationMineral densityBone diseasePatientsClinical practiceVedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018, 25: 580-586. PMID: 30165638, DOI: 10.1093/ibd/izy272.Peer-Reviewed Original ResearchConceptsMedian vedolizumab trough levelsVedolizumab trough levelsC-reactive proteinInflammatory bowel diseaseNormal C-reactive proteinMucosal healingCrohn's diseaseUC patientsBowel diseaseTrough levelsUlcerative colitisClinical managementFourth of patientsTrough level measurementMayo endoscopic scoreCross-sectional studyHigh CRP patientsBiomarker normalizationIBD patientsClinical remissionCRP patientsEndoscopic scoreMucosal ulcersDetectable antibodiesBACKGROUND/Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflammatory Bowel Diseases 2018, 24: 2272-2277. PMID: 29718223, DOI: 10.1093/ibd/izy133.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsBiological TherapyColitis, UlcerativeCrohn DiseaseFemaleFollow-Up StudiesGastrointestinal AgentsHumansInterferon-gamma Release TestsLatent TuberculosisMaleMycobacterium tuberculosisPrognosisProspective StudiesRetrospective StudiesTreatment OutcomeTuberculin TestConceptsLatent tuberculosis infectionInflammatory bowel diseaseTuberculin skin testBiologic therapyLTBI treatmentIBD patientsTuberculosis reactivationBowel diseaseTuberculosis infectionLTBI treatment regimenReactivation of TBRisk of reactivationInterferon-gamma releaseOutcome of treatmentStudy inclusion criteriaMedian annual riskAdalimumab monotherapyIsoniazid therapyTB reactivationCertolizumab pegolPrimary outcomeRetrospective reviewTreatment regimenMedian timeGamma release
2015
Lack of Health Insurance Limits the Benefits of Hepatitis C Virus Screening: Insights from the National Health and Nutrition Examination Hepatitis C Follow-Up Study
Ditah I, Al Bawardy B, Gonzalez H, Saberi B, Ditah C, Kamath P, Charlton M. Lack of Health Insurance Limits the Benefits of Hepatitis C Virus Screening: Insights from the National Health and Nutrition Examination Hepatitis C Follow-Up Study. The American Journal Of Gastroenterology 2015, 110: 1126. PMID: 25756239, DOI: 10.1038/ajg.2015.31.Peer-Reviewed Original ResearchConceptsLack of health insuranceHealth insuranceHepatitis C virusHepatitis C virus screeningPublic health strategiesFollow-up interviewsHealth strategiesHCV careDownstream careScreening programGeneral populationHepatitis C virus infectionHepatitis C virus transmissionControl HCV infectionHCV-infected individualsPositive participantsCareInjected drugsParticipantsInsuranceHCV infectionC virusPotential complicationsPositive individualsScreening